Articles From: Cellular Biomedicine Group Launches Pre-Clinical Research Study for Chronic Obstructive Pulmonary Disease (COPD) to CEMEX Reports Third-Quarter 2014 Results


PALO ALTO, Calif., Oct.
Sign-up for Cellular Biomedicine Group to Present at 2014 China Biotherapy Conference investment picks
PALO ALTO, Calif., Jan.
Sign-up for Cellular Biomedicine Group to Present at OneMedForum and BioTech Showcase in San Francisco investment picks
PALO ALTO, Calif., Jan.
Sign-up for Cellular Biomedicine Group, Inc. Featured on Wide World of Stocks Television investment picks
MADISON, Wis., Nov.
Sign-up for Cellular Dynamics International Reports Third Quarter 2014 Financial Results investment picks
MADISON, Wis., Oct.
Sign-up for Cellular Dynamics to Host Third Quarter 2014 Financial Results Webcast and Call investment picks
MADISON, Wis., Jan.
Sign-up for Cellular Dynamics to Present at 33rd Annual J.P. Morgan Healthcare Conference investment picks
MADISON, Wis., Oct.
Sign-up for Cellular Dynamics to Present at the 2014 Medical Innovation Summit investment picks
MADISON, Wis., Dec.
Sign-up for Cellular Dynamics to Present at the Piper Jaffray 26th Annual Healthcare Conference investment picks
LAWRENCEVILLE, N.J. , Nov.
Sign-up for Celsion Corporation Receives VHP Approval to Initiate OPTIMA Study in Europe investment picks
2014/11/11
Company Completes Acquisition and Integration of EGEN, Inc.; Enrollment Underway in Phase III OPTIMA Study; Initiates Phase II Euro-DIGINTY Study for RCW Breast Cancer; Establishes Clinical Study Plans for EGEN-001 Company to Hold Conference Call on Tuesday, November 11, 2014 at 4:30 p.m. ET LAWRENCEVILLE, N.J. , Nov.
Sign-up for Celsion Corporation Reports Third Quarter 2014 Financial Results investment picks
Lead Immunotherapy Product Candidate GEN-1 to Enter Dose Escalating Clinical Study in the Second Half of 2015 LAWRENCEVILLE, N.J. , Jan.
Sign-up for Celsion Corporation Submits DNA-based Immunotherapy Clinical Protocol to the FDA as Part of a First Line Treatment for Ovarian Cancer investment picks
Data Supportive of GEN-2, an RNAi Carrier for Therapeutic Treatment of Lung Cancer LAWRENCEVILLE, N.J. , Oct.
Sign-up for Celsion Presents Preclinical Data for its TheraSilence™ Platform at the miRNA World Conference Workshop on miRNA Delivery investment picks
NEW YORK and LONDON, Dec.
Sign-up for Celsus Therapeutics Announces Upcoming Presentation at Oppenheimer 25th Annual Healthcare Conference investment picks
2014/10/24
Cementos Pacasmayo S.A.A. (NYSE:CPAC; BVL:CPACASC1) (“the Company” or “Cementos Pacasmayo”) announced today that at a Board meeting held on October 23, 2014, the Company's Board of Directors approved a cash dividend of S/. 0.20 per common and investment share, which represents a total of S/. 116,392,920.60 related to retained earnings as of December 31, 2013, in accordance with what was authorized at the Annual Shareholder’s Meeting on March 25, 2014.
Sign-up for Cementos Pacasmayo S.A.A. Announces Annual Dividend Payment investment picks
2014/10/27
Cementos Pacasmayo S.A.A. and subsidiaries (NYSE: CPAC; BVL: CPACASC1) (“the Company” or “Cementos Pacasmayo”) a Peruvian cement company, announced today its consolidated results for the third quarter (“3Q14”) and nine months (“9M14”) ended September 30, 2014.
Sign-up for Cementos Pacasmayo S.A.A. Announces Consolidated Results for Third Quarter 2014 investment picks
2014/10/24
LIMA, Peru , Oct.
Sign-up for Cementos Pacasmayo to host Third Quarter 2014 Earnings Conference Call & Audio Webcast investment picks
2014/10/30
CEMEX, S.A.B. de C.V. (“CEMEX”) (NYSE: CX) announced today that it has signed binding agreements with Holcim regarding the series of transactions originally announced on August 28, 2013.
Sign-up for CEMEX and Holcim Agree on Series of Transactions in Europe investment picks
2015/1/6
CEMEX, S.A.B. de C.V. (“CEMEX”) (NYSE: CX) announced today that it has closed the series of transactions with Holcim, originally announced on August 28, 2013 and supplemented on October 30, 2014.
Sign-up for CEMEX and Holcim Close Series of Transactions in Europe investment picks
2014/11/3
CEMEX, S.A.B. de C.V. (“CEMEX”) (NYSE: CX) announced today that it has received U.S.$515 million of commitments from banks that have agreed to join the credit agreement entered into on September 30, 2014 (the “Credit Agreement”). Following the completion of customary closing conditions, the banks that provided the new commitments will accede the Credit Agreement as additional lenders, increasing the total amount of the Credit Agreement from U.S.$1.35 billion to U.S.$1.87 billion.
Sign-up for CEMEX Increases New Bank Loan to U.S.$1.87 Billion and Successfully Concludes Amendment to Facilities Agreement investment picks
2014/10/23
CEMEX, S.A.B. de C.V. ("CEMEX") (NYSE: CX), announced today that consolidated net sales reached approximately U.S.$4.1 billion during the third quarter of 2014, an increase of 4% on a like-to-like basis for the ongoing operations and adjusting for currency fluctuations, versus the comparable period in 2013.
Sign-up for CEMEX Reports Third-Quarter 2014 Results investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Cellular Biomedicine Group Launches Pre-Clinical Research Study for Chronic Obstructive Pulmonary Disease (COPD) to CEMEX Reports Third-Quarter 2014 Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent